{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T19:00:05Z","timestamp":1763578805469,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T00:00:00Z","timestamp":1631232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T00:00:00Z","timestamp":1631232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Diffuse Large B Cell Lymphoma (DLBCL) is the most common type of Non-Hodgkin Lymphoma (NHL).\u00a0The aim of this study was to assess the clinico pathological characteristics of DLBCL specifically, among the affected individuals residing in Northern areas of Pakistan who had not been previously included in major lymphoma studies due to their remote location.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Mean age of the patients was 49.7\u00a0years. Male: female ratio was 1.5:1. Primary site was lymph node in 99 (71.74%) patients, out of which, 36 (26.09%) patients had B symptoms and 19 (13.77%) patients had stage IV disease. 39 (28.26%) patients had\u00a0primary extra nodal involvement,\u00a04 (2.90%) patients had B symptoms and 3 (2.17%) had stage IV disease.\u00a0Extra nodal sites involved in primary extra nodal DLBCL were gastrointestinal tract (GIT) 19 (48.72%), tonsils 6 (15.38%), spine 4 (10.26%), soft tissue swelling 3 (7.69%), parotid gland 2 (5.13%), thyroid 2 (5.13%) central nervous system (CNS) 1 (2.56), breast 1 (2.56%) and bone marrow 1 (2.56%). Our study revealed increased percentage of patients with nodal DLBCL in\u00a0stage IV and with B symptoms. Few patients with primary extra nodal DLBCL had B symptoms and stage IV disease at presentation. GIT was the most common site of involvement in primary extra nodal DLBCL.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13104-021-05768-5","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T18:03:04Z","timestamp":1631296984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinicopathological spectrum of Diffuse Large B Cell lymphoma: a study targeting population yet unexplored in Pakistan"],"prefix":"10.1186","volume":"14","author":[{"given":"H.","family":"Mahmood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8211-4639","authenticated-orcid":false,"given":"M.","family":"Habib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Aslam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Khursheed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Habib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Faheem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,10]]},"reference":[{"issue":"10091","key":"5768_CR1","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","volume":"390","author":"JO Armitage","year":"2017","unstructured":"Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet. 2017;390(10091):298\u2013310. https:\/\/doi.org\/10.1016\/S0140-6736(16)32407-2.","journal-title":"Lancet"},{"issue":"2","key":"5768_CR2","first-page":"103","volume":"26","author":"R Shahid","year":"2016","unstructured":"Shahid R, Gulzar R, Avesi L, Hassan S, Danish F, Mirza T. Immunohistochemical profile of Hodgkin and non\u2013Hodgkin lymphoma. J Coll Physicians Surg Pak. 2016;26(2):103\u20137.","journal-title":"J Coll Physicians Surg Pak"},{"issue":"3","key":"5768_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1515\/fco-2015-0013","volume":"6","author":"K Ola","year":"2015","unstructured":"Ola K, Amany H, Yasser AS, Asmaa S, Mohammad A. Clinicopathological profile and outcome of extranodal diffuse large B-cell NHL Egyptian National Cancer Institute Experience. Forum Clin Oncol. 2015;6(3):8\u201312.","journal-title":"Forum Clin Oncol"},{"issue":"5","key":"5768_CR4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/PPO.0b013e31826aee97","volume":"18","author":"MP Menon","year":"2012","unstructured":"Menon MP, Pittaluga S, Jaffe ES. The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification. Cancer J. 2012;18(5):411\u201320.","journal-title":"Cancer J"},{"key":"5768_CR5","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1186\/s13104-019-4447-1","volume":"12","author":"N Alyahya","year":"2019","unstructured":"Alyahya N, Adiga B, Alwadei A, et al. The clinico-pathological profile of non-Hodgkin\u2019s lymphoma in Aseer region of Saudi Arabia. BMC Res Notes. 2019;12:418. https:\/\/doi.org\/10.1186\/s13104-019-4447-1.","journal-title":"BMC Res Notes"},{"issue":"17","key":"5768_CR6","doi-asserted-by":"publisher","first-page":"7207","DOI":"10.7314\/APJCP.2014.15.17.7207","volume":"15","author":"H Mertsoylu","year":"2014","unstructured":"Mertsoylu H, Muallaoglu S, Besen AA, Erdogdu S, Sezer A, Sedef AM, et al. Primary extranodal non-Hodgkins lymphoma: clinicopathological features, survival and treatment outcome in two cancer centers of southern Turkey. Asian Pac J Cancer Prev. 2014;15(17):7207\u201311.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"4","key":"5768_CR7","first-page":"605","volume":"64","author":"MH Bangash","year":"2014","unstructured":"Bangash MH, Hussain I, Zakaria M, Piracha MN. Pattern Of extranodal involvement in non Hodgkins lymphoma. PAFMJ. 2014;64(4):605\u20138.","journal-title":"PAFMJ"},{"issue":"2","key":"5768_CR8","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3126\/ijasbt.v3i2.12756","volume":"3","author":"MZ Nawaz","year":"2015","unstructured":"Nawaz MZ, Bilal M, Mehmood MA, Asgher M. Prevalence of Lymphoma Cancer in Punjab, Pakistan. Int J Appl Sci Biotechnol. 2015;3(2):342\u20136.","journal-title":"Int J Appl Sci Biotechnol"},{"issue":"1","key":"5768_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12957-018-1429-z","volume":"16","author":"R Idrees","year":"2018","unstructured":"Idrees R, Fatima S, Abdul-Ghafar J, Raheem A, Ahmad Z. Cancer prevalence in Pakistan: meta-analysis of various published studies to determine variation in cancer figures resulting from marked population heterogeneity in different parts of the country. World J Surg Oncol. 2018;16(1):129. https:\/\/doi.org\/10.1186\/s12957-018-1429-z.","journal-title":"World J Surg Oncol"},{"issue":"2","key":"5768_CR10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/S1726-4901(08)70076-5","volume":"71","author":"A Zeb","year":"2008","unstructured":"Zeb A, Rasool A, Nasreen S. Cancer incidence in the districts of Dir (Northwest Frontier Province), Pakistan: a preliminary study. J Chin Med Assoc. 2008;71(2):62\u20135. https:\/\/doi.org\/10.1016\/S1726-4901(08)70076-5.","journal-title":"J Chin Med Assoc"},{"issue":"5","key":"5768_CR11","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10552-019-01155-5","volume":"30","author":"A Miranda-Filho","year":"2019","unstructured":"Miranda-Filho A, Pi\u00f1eros M, Znaor A, Marcos-Gragera R, Steliarova-Foucher E, Bray F. Global patterns and trends in the incidence of non-Hodgkin lymphoma. Cancer Causes Control. 2019;30(5):489\u201399. https:\/\/doi.org\/10.1007\/s10552-019-01155-5.","journal-title":"Cancer Causes Control"},{"issue":"1","key":"5768_CR12","first-page":"10","volume":"4","author":"B Vannata","year":"2015","unstructured":"Vannata B, Zucca E. Primary extranodal B-cell lymphoma: current concepts and treatment strategies. Chin Clin Oncol. 2015;4(1):10.","journal-title":"Chin Clin Oncol"},{"issue":"2020","key":"5768_CR13","doi-asserted-by":"publisher","first-page":"2981585","DOI":"10.1155\/2020\/2981585","volume":"21","author":"Y Sun","year":"2020","unstructured":"Sun Y, Qiao X, Jiang C, Liu S, Zhou Z. Texture analysis improves the value of pretreatment 18F-FDG PET\/CT in predicting interim response of primary gastrointestinal diffuse large B-cell lymphoma. Contrast Media Mol Imaging. 2020;21(2020):2981585. https:\/\/doi.org\/10.1155\/2020\/2981585.","journal-title":"Contrast Media Mol Imaging"},{"issue":"1","key":"5768_CR14","doi-asserted-by":"publisher","first-page":"7070","DOI":"10.4081\/hr.2018.7070","volume":"10","author":"S Boussios","year":"2018","unstructured":"Boussios S, Zerdes I, Vassou A, Bareta E, Seraj E, Papoudou-Bai A, Pavlidis N, Batistatou A, Pentheroudakis G. Extranodal diffuse large B-cell lymphomas: a retrospective case series and review of the literature. Hematol Rep. 2018;10(1):7070. https:\/\/doi.org\/10.4081\/hr.2018.7070.","journal-title":"Hematol Rep"},{"issue":"3","key":"5768_CR15","doi-asserted-by":"publisher","first-page":"251","DOI":"10.4103\/ijmpo.ijmpo_82_16","volume":"38","author":"A Pai","year":"2017","unstructured":"Pai A, Kannan T, Balambika RG, Vasini V. A study of clinical profile of primary extranodal lymphomas in a tertiary care institute in South India. Indian J Med Paediatr Oncol. 2017;38(3):251\u20135.","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"9","key":"5768_CR16","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.3389\/fonc.2019.01198","volume":"12","author":"X Yin","year":"2019","unstructured":"Yin X, Xu A, Fan F, Huang Z, Cheng Q, Zhang L, Sun C, Hu Y. Incidence and mortality trends and risk prediction nomogram for extranodal diffuse large B-cell lymphoma: an analysis of the surveillance, epidemiology, and end results database. Front Oncol. 2019;12(9):1198. https:\/\/doi.org\/10.3389\/fonc.2019.01198.","journal-title":"Front Oncol"},{"issue":"9","key":"5768_CR17","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1038\/bjc.2015.94","volume":"112","author":"A Smith","year":"2015","unstructured":"Smith A, Crouch S, Lax S, Li J, Painter D, Howell D, et al. Lymphoma incidence, survival and prevalence 2004\u20132014: sub-type analyses from UKs Haematological Malignancy Research Network. Br J Cancer. 2015;112(9):1575\u201384.","journal-title":"Br J Cancer"},{"issue":"2","key":"5768_CR18","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/bjh.15444","volume":"185","author":"D Chihara","year":"2019","unstructured":"Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, Fayad L, Fowler NH, Cheah CY. Stage I non-Hodgkin lymphoma: difference in survival outcome by primary extranodal site of involvement. Br J Haematol. 2019;185(2):334\u20138. https:\/\/doi.org\/10.1111\/bjh.15444.","journal-title":"Br J Haematol"},{"issue":"1","key":"5768_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijrobp.2015.01.009","volume":"92","author":"J Yahlom","year":"2015","unstructured":"Yahlom J, Illlidge T, Specht L, Hoppe RT, Li YX, Tsang R, et al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2015;92(1):11\u201331.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"5768_CR20","doi-asserted-by":"publisher","first-page":"200","DOI":"10.4103\/sajc.sajc_65_18","volume":"7","author":"A Gogia","year":"2018","unstructured":"Gogia A, Das CK, Kumar L, Sharma A, Tiwari A, Sharma MC, Mallick S. Diffuse large B-cell lymphoma: an institutional analysis. South Asian J Cancer. 2018;7(3):200\u20132. https:\/\/doi.org\/10.4103\/sajc.sajc_65_18.","journal-title":"South Asian J Cancer"},{"issue":"1","key":"5768_CR21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.21147\/j.issn.1000-9604.2019.01.10","volume":"31","author":"Y Shi","year":"2019","unstructured":"Shi Y, Han Y, Yang J, Liu P, He X, Zhang C, Zhou S, Zhou L, Qin Y, Song Y, Liu Y, Wang S, Jin J, Gui L, Sun Y. Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: analysis of 1085 WHO classified cases in a single institution in China. Chin J Cancer Res. 2019;31(1):152\u201361. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2019.01.10.","journal-title":"Chin J Cancer Res"},{"key":"5768_CR22","first-page":"1602","volume":"16","author":"H Shen","year":"2018","unstructured":"Shen H, Wei Z, Zhou D, Zhang Y, Han X, Wang W, Zhang L, Yang C, Feng J. Primary extra-nodal diffuse large B-cell lymphoma: a prognostic analysis of 141 patients. Oncol Lett. 2018;16:1602\u201314.","journal-title":"Oncol Lett"},{"issue":"6","key":"5768_CR23","first-page":"1526","volume":"20","author":"D Yazilitas","year":"2015","unstructured":"Yazilitas D, Ozdemir N, Hoazade C, Bozkaya Y, Yazici O, Sendur MA, et al. A retrospective comparison of early stage primary extranodal with nodal non\u2013Hodgkin lymphoma patients: a single center experience. J BUON. 2015;20(6):1526\u201333.","journal-title":"J BUON"},{"issue":"10","key":"5768_CR24","doi-asserted-by":"publisher","first-page":"4889","DOI":"10.7314\/APJCP.2012.13.10.4889","volume":"13","author":"S Padhi","year":"2012","unstructured":"Padhi S, Paul TR, Challa S, Prayaga AK, Rajappa S. Primary extranodal non Hodgkin lymphoma: a 5 year retrospective analysis. Asian Pacific J Cancer Prev. 2012;13(10):4889\u201395.","journal-title":"Asian Pacific J Cancer Prev"},{"issue":"3","key":"5768_CR25","first-page":"75","volume":"4","author":"A Tariq","year":"2015","unstructured":"Tariq A, Khurshid A, Mehmood Y. Potential risk factors and prevalence trend of diffuse large beta cell lymphoma in Pakistani population. Int J Pharm Res Allied Sci. 2015;4(3):75\u201385.","journal-title":"Int J Pharm Res Allied Sci"},{"issue":"3","key":"5768_CR26","first-page":"412","volume":"35","author":"U Bukhari","year":"2015","unstructured":"Bukhari U, Jamal S, Lateef F. Non Hodgkin lymphoma\u2014a study. Pak Oral Dental J. 2015;35(3):412\u20135.","journal-title":"Pak Oral Dental J"},{"issue":"1","key":"5768_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4038\/cmj.v60i1.7143","volume":"60","author":"TS Waravita","year":"2015","unstructured":"Waravita TS, Wijetunge TS, Ratnatunga NV. Pattern of lymphoma subtypes in a cohort of Sri Lankan patients. Ceylon Med J. 2015;60(1):13\u20137.","journal-title":"Ceylon Med J"},{"issue":"15","key":"5768_CR28","first-page":"25","volume":"1","author":"AA Abdullah","year":"2014","unstructured":"Abdullah AA, Bakhubaira SM, Al- Kahiry W, Moshara GH. Pattern of diffuse large B cell lymphoma(DLBCL) in Aden, Yemen. Gulf J Oncol. 2014;1(15):25\u201331.","journal-title":"Gulf J Oncol"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-021-05768-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-021-05768-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-021-05768-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,11]],"date-time":"2021-09-11T06:02:45Z","timestamp":1631340165000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-021-05768-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,10]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5768"],"URL":"https:\/\/doi.org\/10.1186\/s13104-021-05768-5","relation":{},"ISSN":["1756-0500"],"issn-type":[{"type":"electronic","value":"1756-0500"}],"subject":[],"published":{"date-parts":[[2021,9,10]]},"assertion":[{"value":"12 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved according to the corresponding Ethics Committee- Institutional Review Board of Nuclear Medicine Oncology & Radiotherapy Institute. Administrative permission for accessing the raw data described in the study and conduct of this study was granted by research training and monitoring cell (RTMC) of Nuclear Medicine, Oncology & Radiotherapy Institute.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"The authors declare that they have no competing interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"354"}}